论文部分内容阅读
慢性乙型肝炎抗病毒治疗的研究有了明显的进展。1998年前,抗乙型肝炎病毒(HBV)注册药物只有标准α干扰素;1998年之后,核苷(酸)类似物拉米夫定、阿德福韦酯、恩替卡韦和替比夫定相继用于临床;2005年聚乙二醇化干扰素α-2a(PAGasys)批准上市用于慢性乙型肝炎治疗。这些研究的进展
There have been significant advances in the research of antiviral treatment of chronic hepatitis B. Prior to 1998, only anti-hepatitis B virus (HBV) registered drugs had standard interferon alpha; after 1998, the nucleoside (acid) analogs lamivudine, adefovir dipivoxil, entecavir and telbivudine were used in succession In clinical; pegylated interferon alfa-2a (PAGasys) approved for marketing in 2005 for chronic hepatitis B treatment. The progress of these studies